Should the European Medicines Agency consider ageing a disease?

Show simple item record Marín Penella, Guillermo 2024-01-16T12:36:16Z
dc.description.abstract The classification of ageing as a disease is fundamental to developing new pharmacological strategies that can target said phenomenon. The European Medicines Agency does not do this and maintains a questionable perspective based on the traditional naturalistic argument and the value-free ideal. An alternative is proposed which, inspired by consequentialism, is committed to considering ageing as a disease in European regulatory contexts as long as the ethical consequences are desirable. Within a realistic framework, I show that making this decision would have moderate positive effects such as increased knowledge about antiageing pharmacology or potential greater chances of completing vital projects. Furthermore, we will see that the main arguments used by critics to show that the negative effects outweigh the positive ones are not sound. Therefore, I conclude that it would be beneficial for the European Medicines Agency to change its position on ageing.
dc.format application/pdf
dc.relation.ispartof Bioethics, 2024
dc.rights , 2024
dc.subject.classification Filosofia
dc.subject.classification 36 - Benestar i problemes socials. Treball social. Ajuda social. Vivenda. Assegurances
dc.subject.other Philosophy
dc.subject.other 36 - Safeguarding the mental and material necessities of life Social work. Social aid. Housing. Insurance
dc.title Should the European Medicines Agency consider ageing a disease?
dc.type info:eu-repo/semantics/article 2024-01-16T12:36:16Z info:eu-repo/date/embargoEnd/2100-01-01
dc.embargo 2100-01-01
dc.rights.accessRights info:eu-repo/semantics/embargoedAccess

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Repository

Advanced Search


My Account